Avutometinib(Avutometinib) - 药物靶点：BRAF x CRAF x MEK_在研适应症：交界性卵巢浆液性肿瘤，卵巢浆液性肿瘤，KRAS 突变的低级别浆液性卵巢癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Avutometinib Potassium、CH 5127566、CH-5126766

+ [8]

靶点

BRAF x CRAF x MEK

作用方式

抑制剂

作用机制

BRAF抑制剂(丝氨酸/苏氨酸蛋白激酶B-raf抑制剂)、CRAF抑制剂(C-Raf激酶抑制剂)、MEK抑制剂(双特异性丝裂原活化蛋白激酶激酶抑制剂)

治疗领域

肿瘤内分泌与代谢疾病泌尿生殖系统疾病+ [9]

在研适应症

交界性卵巢浆液性肿瘤卵巢浆液性肿瘤KRAS 突变的低级别浆液性卵巢癌+ [38]

非在研适应症

大肠腺癌晚期结直肠腺癌KRAS 突变结直肠癌+ [1]

原研机构

F. Hoffmann-La Roche Ltd.

在研机构

Verastem, Inc.

Chugai Pharmaceutical Co., Ltd.

Eli Lilly & Co.

+ [2]

非在研机构

Hoffmann-La Roche, Inc.

权益机构

Amgen, Inc.

Chugai Pharmaceutical Co., Ltd.

Memorial Sloan Kettering Cancer Center

+ [1]

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)-

特殊审评优先审评 (美国)、快速通道 (美国)、孤儿药 (美国)、加速批准 (美国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

分子式C21H18FN5O5S

InChIKeyLMMJFBMMJUMSJS-UHFFFAOYSA-N

CAS号946128-88-7

关联

28

项与 Avutometinib 相关的临床试验

NCT06369259

/ Recruiting临床2期IIT

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.

开始日期2025-02-24

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT06630260

/ Recruiting临床1/2期IIT

A Phase 1/2 Trial of the Doublet Combination of Avutometinib and Defactinib and As a Triplet in Combination with Temozolomide in Patients with High Grade Malignant Brain Tumours Within the 5G Platform

The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended Phase 2 dose (RP2D). In the Phase 1b of this study parallel biomarker defined arms will be opened, initially in the relapsed GMB setting, enrolling 12 patients onto each arm. These patients will be treated with avutometinib and defactinib double therapy. Avutometinib will be administered orally at 3.2mg twice a week (e.g., on Monday / Thursday or Tuesday / Friday) with or without a meal. The total weekly dose of avutometinib is 6.4mg. Defactinib will be administered orally, at 200mg, twice a day within 30 min after a meal. The total daily dose of defactinib is 400mg.
Once a treatment in any biomarker arm has met the "GO" decision (≥3 successes/12 patients) for relapsed GBM in Phase 1b, that arm can progress to Phase 2. The primary objective of Phase 2 is to determine the antitumour activity of investigational agents administered at the RP2D in patients with molecularly defined malignant brain tumours.

开始日期2024-11-15

申办/合作机构

The Institute of Cancer Research: Royal Cancer Hospital

[+5]

NCT06682572

/ Recruiting临床2期

A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Japanese Patients

This study will confirm the safety and efficacy of avutometinib in combination with defactinib in Japanese patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

开始日期2024-10-30

申办/合作机构

Verastem, Inc.

100 项与 Avutometinib 相关的临床结果

登录后查看更多信息

100 项与 Avutometinib 相关的转化医学

登录后查看更多信息

100 项与 Avutometinib 相关的专利（医药）

登录后查看更多信息

72

项与 Avutometinib 相关的文献（医药）

2025-05-01·Journal of Orthopaedic Translation

RO5126766 attenuates osteoarthritis by inhibiting osteoclastogenesis and protecting chondrocytes through mediating the ERK pathway

Article

作者: Wu, Zuoxing ; Ling, Zemin ; Yuan, Xiwen ; Han, Jie ; Shen, Rong ; Wang, Han ; Luo, Zhengqiong ; Guo, Chenyang ; Huang, Jianming ; Yuan, Guixin ; Shi, Fan ; Chen, Zihan ; He, Xuemei ; Ma, Zheru ; Xu, Ren ; Meng, Lin

Background:

Osteoarthritis (OA) is a degenerative joint disease that remains challenging to treat due to lack of complete understanding of its pathogenesis. Previous studies have identified RO5126766 (RO) as a small molecule compound that inhibited RAF/MEK-ERK pathway and garnered much interest for its anti-cancer properties. But its role in the treatment of OA remains unclear.

Methods:

This study employed the anterior cruciate ligament transection (ACLT) procedure to create an OA model in mice. The effects of RO on pathological changes in articular cartilage and subchondral bone were assessed using micro-CT and histological staining. Mice received peritoneal injections of RO at 1 mg/kg and 5 mg/kg biweekly for 4 weeks after ACLT, while control mice received saline. In vitro, bone marrow-derived macrophages were cultured to examine the effects of RO on osteoclast activation using immunofluorescence, TRAP staining, and bone resorption assays. The inflammatory degeneration of chondrocytes and gene expression levels were evaluated using staining and RT-qPCR. Western blot and immunohistochemistry were used to analyze MAPK signaling and autophagy-related protein expression, investigating RO's molecular mechanism in OA treatment. Human single-cell data were also analyzed to identify genes and pathways upregulated in OA tissues.

Results:

Our findings showed that RO protects subchondral bone by inhibiting osteoclast formation in the ACLT mouse model of OA. In vitro, RO was shown to inhibit osteoclast differentiation and reduce inflammatory degeneration of chondrocytes. Mechanistically, RO counteracted subchondral osteoclast hyperactivation by suppressing the ERK/c-fos/NFATc1 signaling pathway. Additionally, RO inhibited LPS-induced inflammatory degeneration of chondrocytes and enhanced autophagy via the ERK pathway. Single-cell analysis further confirmed significant upregulation of the ERK signaling pathway in human OA tissues.

Conclusions:

Overall, our findings suggested that RO inhibited osteoclast differentiation and protected articular cartilage, suggesting its potential as a novel treatment for OA.

Translational potential of this article:

In this study, we have, for the first time, substantiated the therapeutic potential of RO in the treatment of OA. By demonstrating its ability to inhibit osteoclast differentiation and protect articular cartilage, RO could offer a new avenue for disease-modifying treatments in OA. Thus, this paper provides valuable insights into understanding the molecular mechanisms and treatment of OA.

2025-04-01·INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

Article

作者: Lustgarten, Stephanie ; Oaknin, Ana ; Monk, Bradley J ; Harter, Philipp ; Grisham, Rachel ; Van Nieuwenhuysen, Els ; Colombo, Nicoletta ; Cobb, Lauren ; Mirza, Mansoor Raza ; Lee, Yeh Chen ; Aghajanian, Carol A ; O'Malley, David M ; Oza, Amit M ; Gershenson, David ; Thaker, Premal ; Moore, Kathleen Nadine ; Banerjee, Susana ; Youssoufian, Hagop ; Coleman, Robert L ; Fabbro, Michel ; Choi, Chel Hun

Background:

There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with defactinib has demonstrated efficacy and a consistent safety profile in two clinical trials in recurrent low grade serous ovarian cancer, and a lower discontinuation rate due to adverse events compared with historical rates for standard of care.

Primary Objective:

To compare the progression free survival of the combination of avutometinib with defactinib versus investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer.

Study Hypothesis:

Combination treatment with avutometinib–defactinib will significantly improve progression free survival compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer.

Trial Design:

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301 is a phase 3, randomized, international, open label study designed to compare avutometinib with defactinib versus investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer who have progressed on a previous platinum based therapy. On confirmation of disease progression using a blinded independent central review, patients on the investigator’s choice of treatment arm may cross over to the avutometinib–defactinib arm.

Major Inclusion/Exclusion Criteria:

Patients must have recurrent low grade serous ovarian cancer (KRASmutant or wild-type) and have documented progression (radiographic or clinical) or recurrence of low grade serous ovarian cancer after at least one platinum based chemotherapy regimen. Unlimited additional previous lines of therapy are allowed, including previous MEK/RAF inhibitor. Patients will be excluded if they have co-existing high grade ovarian cancer or had previous treatment with avutometinib, defactinib, or any other FAK inhibitor.

Primary Endpoint:

Progression free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, blinded-independent central review.

Sample Size:

Approximately 270 patients will be randomized in a 1:1 fashion to either the combination avutometinib with defactinib arm (n~135) or the investigator’s choice of treatment arm (n~135).

Estimated Dates for Completing Accrual and Presenting Results:

The estimated primary completion date of RAMP 301 is 2028, and the estimated study completion date is 2031.

Trial Registration:

ClinicalTrials.govNCT06072781

2025-03-01·CANCER CELL

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

Article

作者: Bacchiocchi, Antonietta ; Gutkind, J Silvio ; Adame-Garcia, Sendi R ; Martini, Claudia ; Sato, Kuniaki ; Rigiracciolo, Damiano C ; Officer, Adam ; Ferguson, Fleur M ; Wang, YiYu ; Cervantes-Villagrana, Rodolfo Daniel ; Coma, Silvia ; Pachter, Jonathan A ; Lubrano, Simone ; Aplin, Andrew E ; Arang, Nadia ; Ramirez, Sydney ; Holmen, Sheri L ; Halaban, Ruth ; Faraji, Farhoud ; Anguiano Quiroz, Paola Y

Widespread BRAF mutations result in persistent RAS-RAF-MEK-ERK (MAPK) signaling in melanoma. BRAF (BRAFi) and MEK (MEKi) inhibitors are approved for BRAF V600E melanomas, including those progressing on immunotherapy; however, rapid resistance to these agents highlights the need for novel strategies. Here, transcriptome analysis of BRAF V600E melanomas from patients resistant to BRAFi and MEKi shows activation of focal adhesion signaling. Consistently, BRAFi, MEKi, and the RAF-MEK clamp avutometinib activate focal adhesion kinase (FAK) in melanoma cells. Mechanistically, inhibition of an MAPK-RhoE (RND3) feedback loop results in the adaptive activation of RhoA-FAK-AKT. In turn, FAK inhibitors (FAKi) exert potent pro-apoptotic activity when combined with MAPK pathway inhibition. FAKi plus avutometinib overcomes resistance in multiple models derived from BRAFi plus MEKi-resistant melanoma patients and immunotherapy-resistant syngeneic mouse models. These findings provide a rationale for the development of avutometinib in combination with FAKi for patients with BRAF V600E melanoma progressing on BRAFi plus MEKi or immunotherapy.

94

项与 Avutometinib 相关的新闻（医药）

2025-05-22

·Firstwordpharma

ASCO25: Verastem's doublet posts encouraging response data in pancreatic cancer

Fresh off a regulatory win for its doublet therapy in ovarian cancer, Verastem Oncology is now looking to duplicate that success in pancreatic cancer.The biotech is evaluating Avmapki (avutometinib) and Fakzynja (defactinib) — a RAF/MEK clamp and selective FAK inhibitor, respectively — in combination with chemotherapy in the Phase I/II RAMP 205 study as a front-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).Earlier this month, the FDA approved Avmapki Fakzynja Co-pack for adults with KRAS-mutated, recurrent, low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy after the doublet demonstrated a confirmed overall response rate of 44% in the Phase II RAMP 201 trial. In PDAC, early data from RAMP 205 — shared in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting — showed that the combo led to an overall response rate (ORR) of 83% in a dozen patients. Verastem's shares ticked up about 3% during after-hours trading on Thursday, after initially gaining 12%."The exciting results from the RAMP 205 trial reinforce our commitment to maximising the synergistic potential of the avutometinib plus defactinib combination in other advanced solid tumors," CEO Dan Paterson said in a company release. At the April 25 data cutoff, 60 patients in RAMP 205 were randomised evenly across five different dosing cohorts. According to Verastem, the 12 participants who received dose level 1 — a 2.4-mg dose of Avmapki twice a week, plus 200-mg Avmapki twice-daily for three weeks out of every four — saw "strong and consistent results" with the combination treatment. Eight patients experienced a confirmed partial response, while two have unconfirmed partial responses and remain on treatment. Verastem has selected this regimen for the recommended Phase II dose, and plans to enrol up to 29 patients in the cohort. The biotech has also begun planning a registrational Phase III study evaluating Avmapki and Fakzynja for front-line metastatic PDAC, which it expects to launch next year.

临床结果ASCO会议临床2期临床3期

2025-05-17

·ioncology

妇瘤前沿丨Bradley Monk点评：复发性KRAS突变低级别浆液性卵巢癌治疗新选择

点击蓝字关注我们2025年5月8日，FDA加速批准Avutometinib/Defactinib联合疗法，用于治疗至少接受过1次全身治疗的KRAS突变复发性低级别浆液性卵巢癌（LGSOC）成年患者。[1]此项批准基于II期ENGOT-ov60/RAMP-201/GOG-3052试验（NCT04625270）的结果。该试验结果显示，在57例KRAS突变复发性LGSOC患者中，该联合疗法的确认客观缓解率（ORR）为44%（95%CI: 31%-58%），缓解持续时间（DoR）范围为3.3-31.1个月。美国妇瘤专家Bradley Monk, MD, FACOG, FACS对这项审批予以点评。Bradley Monk, MD, FACOG, FACSFDA加速批准Avutometinib/Defactinib用于治疗KRAS突变复发性低级别浆液性卵巢癌患者，这在临床上有何意义？1Monk：这是FDA首次批准针对低级别浆液性卵巢癌的疗法。大多数卵巢癌病例是高级别浆液性卵巢癌（HGSOC），而LGSOC是一种较为罕见的卵巢癌亚型。70%的LGSOC病例由RAS驱动（MAPK通路）。大约30%的LGSOC病例携带KRAS突变，还可能存在NRAS、BRAF、NF1和其他RAS通路相关基因突变。KRAS突变尤为重要，此次加速批准是针对KRAS突变肿瘤。此项批准基于RAMP 201研究结果。2021年3月，FDA授予Avutometinib/Defactinib用于治疗低级别卵巢癌的突破性疗法认定，该认定基于研究者发起的I期FRAME试验（NCT03875820）的结果。[2]过去约4年以来，我们一直在研究LGSOC这种罕见肿瘤类型（包括约30%的KRAS突变肿瘤）以进行剂量优化。我们最终实现Avutometinib/Defactinib的剂量优化。RAMP 201研究结果计划发表在一份高影响力的临床肿瘤学期刊上。此外，根据加速批准要求，后续需完成III期验证试验，这项名为RAMP 301（NCT06072781）的试验目前已启动。RAF/MEK钳合剂（Avutometinib）和FAK抑制剂（Defactinib）组合如何在作用机制上克服KRAS突变浆液性卵巢癌的生物学复杂性？1Monk：这种药物组合可以改善LGSOC这种罕见肿瘤类型患者的预后。该组合包括口服Avutometinib（一种RAF/MEK钳合剂，能抑制MEK）；以及口服选择性FAK抑制剂Defactinib。该组合在肿瘤患者中的ORR为44%，已获得长期安全性和有效性数据。临床工作者可以立即使用该方案。我们设计RAMP 201试验的理念是，如果能够同时抑制MEK和FAK，就能克服MEK抑制本身固有的耐药性。请谈一谈这种联合方案的给药方案和安全性1Monk：患者每周两次口服3.2 mg的Avutometinib（分别在每周的第1天和第4天）；每日两次口服200 mg的Defactinib。这种联合方案需要在每个周期（4周）的前3周服用，这使得情况更加复杂。该方案包含激酶抑制剂，并且给药方案具有特异性，口服疗法需长期服用。常见的不良反应（AE）包括疲劳、肌肉骨骼疼痛、水肿以及皮疹等。不过，目前有一种积极的缓解策略可以治疗和预防痤疮样皮疹。LGSOC是一种独特的卵巢癌亚型，并非BRCA相关肿瘤，而是一种MAPK相关疾病。一旦确诊LGSOC，就可以进行全身治疗。如果患者在一线治疗后出现疾病进展，并且携带KRAS突变，则可接受Avutometinib/Defactinib治疗。目前，III期RAMP 301试验将继续在美国以及世界各地招募KRAS突变或野生型肿瘤患者。参考文献1.FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. FDA. May 8, 2025. Accessed May 8, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low2. Verastem Oncology receives breakthrough therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer. News release. Verastem, Inc. May 24, 2021. Accessed May 9, 2025. https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-receives-breakthrough-therapy-designation-vs（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

加速审批临床结果临床2期突破性疗法临床3期

2025-05-14

·医药健闻

卡尔蔡司医疗总裁兼CEO换人；罗氏诊断苏州新投资项目奠基；诺和诺德与平安健康达成战略合作 | 日报

全球医疗行业每日重点资讯文 | 苏丁企业动态卡尔蔡司医疗（Carl Zeiss Meditec AG）宣布，其总裁兼首席执行官（CEO）Markus Weber博士将于2025年5月31日正式卸任。自 2025年6月1日起，Maximilian Foerst将接任总裁兼首席执行官（CEO）。此前，他自2009年起担任蔡司大中华区负责人，领导该地区业务发展。联合健康集团(UnitedHealth Group)周二宣布，首席执行官Andrew Witty因“个人原因”将立即卸任。他的职位将由联合健康集团的董事会主席Stephen Hemsley接任。去年联合健康保险公司(UnitedHealthcare)首席执行官Brian Thompson被枪杀，Witty负责领导该子公司度过难关。罗氏诊断产品（苏州）有限公司5月12日举行苏州基地新投资项目奠基仪式，该项目于2024年8月正式签约。这项投资将用于建设诊断试剂和仪器设备生产研发基地的新厂房和设施，并推进关键产品组合的本地化研发和生产，预计2028年正式投产。诺和诺德与平安健康医疗科技有限公司宣布达成战略合作。双方将整合在肥胖症管理及公众健康教育领域的各自优势，共同构建覆盖“认知提升-诊疗干预-长期管理”的全周期服务闭环，助力科学减重理念落地。此次合作中，双方将基于平安健康的数字化生态设立“肥胖症科普专区”。美的医疗旗下万东医疗与巴西VMI集团正式签署战略合作备忘录。根据协议内容，双方将在巴西成立合资公司，重点开展MRI、CT及Cath lab等高端医疗装备的研发与本土化生产。合资企业将设立生产设施与研发中心。诺诚健华全资子公司北京诺诚健华医药科技有限公司与西湖大学签订《战略合作框架协议》与《科研合作协议》。根据协议，北京诺诚健华对共同开展的创新药物研发项目提供前期资金支持，并基于项目进展支付里程碑付款，合计不超过5400万元。公司非执行董事施一公博士为西湖大学校长，西湖大学为公司的关联人，本次协议签订构成关联交易。药石科技与瑞士化学信息学公司Alipheron宣布达成战略合作，双方通过整合药石科技分子砌块独特资源优势与Alipheron领先的化学信息学平台工具，成功构建出包含超570亿新型化合物的超大规模化合物库。这一突破性进展将显著提升药物发现效率，为全球科研人员提供即时可获取的化学空间探索方案。尚高控股子公司InfiniClone Limited正式启动东南亚市场拓展战略，与Total World Marketing泰国公司（TWM）达成战略分销协议，由后者负责InfiniClone分子检测试剂盒及Purelix系列保健品在东南亚市场的推广与销售。InfiniClone分子检测试剂盒基于其核心iPSC技术开发，可分析包括糖尿病、癌症、阿兹海默症等疾病风险基因变异，以及药物反应、皮肤特性、营养代谢等遗传特征。Purelix保健品则可以针对检测结果定制免疫强化、脑神经支持及抗氧化方案。生物医药科技企业望石智慧应用亚马逊云科技的底层基础设施、高性能计算和存储等技术与服务，构建多模态3D分子生成大模型，在降低运维负担与成本的同时，推动人工智能辅助药物设计（AIDD）过程的效率，实现人工智能在医药行业创新应用场景的落地。产业动态北京科兴控股（集团）有限公司与巴西制药企业Eurofarma签署了疫苗合作协议。双方将建立中巴疫苗生产平台，合作生产的多种疫苗不仅供应巴西，还将供应更多的南方国家。专注于基因与细胞治疗的CDMO企业苏州博腾生物制药有限公司宣布与创新疗法研发企业河南省华隆生物技术有限公司达成战略合作。根据协议，博腾生物将为华隆生物提供MATC（多重活化的T淋巴细胞）疗法从工艺优化到注册申报的一站式服务，加快推进MATC细胞疗法的开发。金城医药近日与Theramex HQ UK Limited签署《权益许可和经销协议》，获得用于绝经后妇女雌激素缺乏症状的连续联合激素替代疗法（HRT）的雌二醇黄体酮软胶囊（Bijuva）在中国境内（包括中国大陆、香港和澳门）的独家排他的商业化权益。因美纳推出业界最全面的二级分析解决方案DRAGEN 4.4版本软件（v4.4），包括“开箱即用”的肿瘤学应用，以用于临床研究，并为最新发布的因美纳多组学检测方案提供支持。此外，DRAGEN v4.4延续了DRAGEN软件的一流准确性，并在生殖系结构变异检出方面的准确性提高了30%。美国FDA加速批准Verastem Oncology公司的联合疗法Avmapki Fakzynja Co-pack（avutometinib与defactinib），用于治疗复发性低级别浆液性卵巢癌（LGSOC）成年患者，这些患者曾接受过系统性治疗并且其肿瘤携带KRAS突变。Verastem认为Avmapki Fakzynja Co-Pack是有史以来第一个获得肿瘤学批准的两种新药的口服联合疗法。沃特世宣布Empower软件升级，全面支持怀雅特Wyatt Technology多角度光散射和示差折光仪器系列的生物制剂数据采集和质控分析。这一整合拓展了生物制药实验室使用Empower软件管理关键质量属性的范围。此外，该技术升级将简化从生物制剂开发到质量控制全过程的合规数据采集与提交流程，减少软件验证工作量，可为客户节省多达六个月的软件验证时间。联系美通社+86-10-5953 9500info@prnasia.com

高管变更引进/卖出

100 项与 Avutometinib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15254

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
交界性卵巢浆液性肿瘤	申请上市	美国	Verastem, Inc.	2024-05-24
卵巢浆液性肿瘤	临床3期	澳大利亚	Verastem, Inc.	2024-03-18
卵巢浆液性肿瘤	临床3期	比利时	Verastem, Inc.	2024-03-18
卵巢浆液性肿瘤	临床3期	加拿大	Verastem, Inc.	2024-03-18
卵巢浆液性肿瘤	临床3期	法国	Verastem, Inc.	2024-03-18
卵巢浆液性肿瘤	临床3期	德国	Verastem, Inc.	2024-03-18
卵巢浆液性肿瘤	临床3期	爱尔兰	Verastem, Inc.	2024-03-18
卵巢浆液性肿瘤	临床3期	意大利	Verastem, Inc.	2024-03-18
卵巢浆液性肿瘤	临床3期	荷兰	Verastem, Inc.	2024-03-18
卵巢浆液性肿瘤	临床3期	新西兰	Verastem, Inc.	2024-03-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


phase 1 trial (AACR2025)	临床1期	转移性乳腺癌 CDK4/6 inhibitor (CDK4/6i)	16	Avutometinib 3.2 mg PO BIW	壓壓網廠醖醖遞繭艱鏇(觸鏇選憲壓糧衊顧選糧) = 繭鹽壓艱積憲鑰鏇繭顧網糧膚遞製選顧醖憲夢 (憲齋淵鏇鑰鑰遞夢製醖 ) 更多	积极	2025-04-28
NCT05074810 (RAMP 203, BusinessWire) 人工标引	临床1/2期	KRAS G12C突变非小细胞肺癌 KRAS G12C	3	Defactinib，Avutometinib, sotorasib	衊憲衊衊廠醖蓋糧遞壓(網願簾廠築窪壓觸艱衊) = None 襯廠憲廠觸艱構簾餘艱 (餘醖蓋築窪襯獵膚構築 ) 更多	积极	2024-12-18
NCT04625270 (ENGOT-OV60/GOG-3052/RAMP 201 Part A, SGO2024)	临床2期	卵巢浆液性肿瘤 RAS/MAPK pathway alterations	29	Avutometinib + Defactinib	窪願壓鏇醖鑰築簾鏇獵(鑰鏇遞選窪襯築簾繭糧) = 夢遞壓願艱顧艱糧鑰鹽憲鹽蓋遞襯醖觸衊衊艱 (鏇構築選顧艱鑰觸鏇襯, 26 ~ 64)	积极	2024-11-01
NCT04625270 (RAMP 201 \| ENGOTov60/GOG3052, Company_Website \| FDA) 人工标引	临床2期	卵巢浆液性肿瘤	109	Avutometinib and Defactinib Combination	鹽範鬱觸膚選夢顧鬱憲(築膚醖鹽餘衊糧構鏇網) = 蓋鹹獵醖觸齋艱獵顧憲繭蓋鏇鏇鏇獵艱廠襯鹽 (糧獵觸廠艱廠蓋簾鬱壓, 23 ~ 41) 更多	积极	2024-10-17
				Avutometinib and Defactinib Combination (KRAS mutant)	鹽範鬱觸膚選夢顧鬱憲(築膚醖鹽餘衊糧構鏇網) = 鹽壓廠選壓築壓齋淵膚繭蓋鏇鏇鏇獵艱廠襯鹽 (糧獵觸廠艱廠蓋簾鬱壓, 31 ~ 58) 更多
NCT05669482 (RAMP 205, ASCO2024) 人工标引	临床1/2期	转移性胰腺导管腺癌一线	18	Avutometinib/defactinib + gemcitabine/nab-paclitaxel	鹽網鹹顧憲繭夢鹹構齋(廠鹹廠膚選鹹蓋醖觸醖) = 醖構鏇壓鏇齋築鏇顧遞構構蓋構壓鹹憲鹽鏇憲 (壓齋鹽構顧壓廠襯鏇築 ) 更多	积极	2024-05-24
NCT05074810 (RAMP 203, Corporate Publications) 人工标引	临床1/2期	KRAS G12C突变非小细胞肺癌 KRAS G12C	-	Avutometinib+sotorasib	鑰淵蓋衊鏇鏇網鹹獵襯(衊憲鏇鬱鏇網餘襯蓋憲) = Avutometinib 4.0 mg PO BIW 21/28 days + sotorasib 960 mg PO QD 28/28 days 淵遞餘淵襯衊網蓋觸糧 (鹹遞憲築襯範膚選構網 )	积极	2023-10-14
NCT04625270 (ENGOT-Ov60/GOG-3052/RAMP 201, ESGO2023)	临床2期	卵巢浆液性肿瘤 KRAS mutant \| KRAS wild-type	151	Avutometinib	願壓獵範壓襯糧構願廠(淵廠衊鹹糧鹹鹹衊遞夢) = 簾願鏇襯簾觸鑰願顧選鹹範艱蓋鏇鬱願壓淵顧 (顧願壓選窪顧簾觸衊壓 ) 更多	积极	2023-09-27
				Avutometinib + Defactinib	願壓獵範壓襯糧構願廠(淵廠衊鹹糧鹹鹹衊遞夢) = 積齋製淵選鏇襯醖廠繭鹹範艱蓋鏇鬱願壓淵顧 (顧願壓選窪顧簾觸衊壓 ) 更多
NCT04625270 (RAMP 201, ASCO 12023 \| ASCO 22023) 人工标引	临床2期	卵巢癌	121	avutometinib 4 mg	構衊願積範衊遞廠鹽網(製簾選範醖廠廠鬱醖壓) = 醖築繭構夢廠鏇襯壓製憲願齋憲鏇製鹽鹽簾築 (觸簾鬱構網遞築鹽顧網 ) 更多	积极	2023-05-31
				avutometinib 3.2 mg+defactinib 200 mg	構衊願積範衊遞廠鹽網(製簾選範醖廠廠鬱醖壓) = 觸蓋製鑰簾壓網網獵繭憲願齋憲鏇製鹽鹽簾築 (觸簾鬱構網遞築鹽顧網 ) 更多
NCT04620330 (RAMP 202, ASCO 12023 \| ASCO 22023) 人工标引	临床2期	KRAS突变非小细胞肺癌 KRAS G12V Mutantion	35	Avutometinib	鑰遞齋鹹艱淵顧窪製範(蓋獵壓範範艱鏇積構製) = 糧網選窪夢築鹹簾鹽築築廠鹹製築餘鑰憲鑰廠 (製鬱獵窪淵築壓構襯襯 )	不佳	2023-05-26
				Defactinib+Avutometinib	鑰遞齋鹹艱淵顧窪製範(蓋獵壓範範艱鏇積構製) = 築廠壓鏇淵淵鑰齋廠廠築廠鹹製築餘鑰憲鑰廠 (製鬱獵窪淵築壓構襯襯 )
NCT04620330 (RAMP 202, Corporate Publications) 人工标引	临床2期	非小细胞肺癌	56	VS-6766+defactinib (KRAS G12V NSCLC)	艱簾構衊顧製餘齋齋艱(齋遞鏇鹹齋夢窪壓襯廠) = 積觸繭網鏇獵淵鏇簾憲鑰艱鏇簾網餘齋鬱鏇簾 (餘選願膚艱憲壓網憲製 ) 更多	不佳	2022-10-04
				VS-6766+defactinib (non-G12V KRAS mutations)	艱簾構衊顧製餘齋齋艱(齋遞鏇鹹齋夢窪壓襯廠) = 鬱醖醖齋獵餘簾製糧淵鑰艱鏇簾網餘齋鬱鏇簾 (餘選願膚艱憲壓網憲製 ) 更多